MXCT vs NVAX vs MRNA vs BTBT vs BNTX

For growth investors, Bit Digital, Inc.

(BTBT) is the stronger pick with 264. 6% revenue growth year-over-year, versus -39. 2% for Moderna, Inc. (MRNA). Novavax, Inc. (NVAX) offers the better valuation at 3. 6x trailing P/E, making it the more compelling value choice. Analysts rate Novavax, Inc. (NVAX) a "Buy" — based on 23 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novavax, Inc.

(NVAX) is the cheapest at 3. 6x versus Bit Digital, Inc. at 9. 2x.

Over the past 5 years, BioNTech SE (BNTX) delivered a total return of -48.

2%, compared to -94. 9% for MaxCyte, Inc. (MXCT). Over 10 years, the gap is even starker: BNTX returned +568. 1% versus MXCT's -94. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), BioNTech SE (BNTX) is the lower-risk stock at 1.

14β versus Bit Digital, Inc. 's 3. 37β — meaning BTBT is approximately 195% more volatile than BNTX relative to the S&P 500. On balance sheet safety, BioNTech SE (BNTX) carries a lower debt/equity ratio of 1% versus 22% for Moderna, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Bit Digital, Inc.

(BTBT) is pulling ahead at 264. 6% versus -39. 2% for Moderna, Inc. (MRNA). On earnings-per-share growth, the picture is similar: Novavax, Inc. grew EPS 306. 5% year-over-year, compared to -62. 8% for BioNTech SE. Over a 3-year CAGR, MXCT leads at -9. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novavax, Inc.

(NVAX) is the more profitable company, earning 39. 2% net margin versus -145. 2% for Moderna, Inc. — meaning it keeps 39. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NVAX leads at 50. 1% versus -158. 1% for MRNA. At the gross margin level — before operating expenses — NVAX leads at 93. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

In this comparison, BTBT (0.

3% yield) pays a dividend. MXCT, NVAX, MRNA, BNTX do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, BioNTech SE (BNTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

14), +568. 1% 10Y return). Novavax, Inc. (NVAX) carries a higher beta of 2. 11 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (BNTX: +568. 1%, NVAX: -90. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (MXCT (Healthcare) and NVAX (Healthcare) and MRNA (Healthcare) and BTBT (Financial Services) and BNTX (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: MXCT is a small-cap quality compounder stock; NVAX is a small-cap high-growth stock; MRNA is a mid-cap quality compounder stock; BTBT is a small-cap high-growth stock; BNTX is a mid-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.